Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy M Gulick

Showing results (41-50 of 155) with videos related to

Pageof 16
Sort By:
Journal of the American Statistical Association|January 19, 2013
Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095Li Li, Joseph J Eron, Heather Ribaudo, et al.
Open Forum Infectious Diseases|February 23, 2019
Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral TherapyPriya Bhagwat, Shashi N Kapadia, Heather J Ribaudo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Case-control study of diabetes mellitus in HIV-infected patientsCecilia Yoon, Roy M Gulick, Donald R Hoover, et al.
HIV Clinical Trials|February 6, 2010
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)David B Clifford, Scott Evans, Yijun Yang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095Bruce R Schackman, Heather J Ribaudo, Amy Krambrink, et al.
AIDS (London, England)|February 4, 2012
Novel clinical trial designs for the development of new antiretroviral agentsNina Mani, Jeffrey Murray, Roy M Gulick, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 13, 2010
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2W David Hardy, Roy M Gulick, Howard Mayer, et al.
The Journal of Infectious Diseases|March 20, 2004
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359Courtney V Fletcher, Hongyu Jiang, Richard C Brundage, et al.
Antiviral Therapy|February 22, 2007
Design issues in initial HIV-treatment trials: focus on ACTG A5095Heather J Ribaudo, Daniel R Kuritzkes, Bruce R Schackman, et al.
The Journal of Infectious Diseases|November 4, 2005
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virusKristen M Marks, Lydia M Petrovic, Andrew H Talal, et al.
Pageof 16

Showing results (41-50 of 155) with videos related to

Sort By:
Pageof 16
Journal of the American Statistical Association|January 19, 2013
Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095Li Li, Joseph J Eron, Heather Ribaudo, et al.
Open Forum Infectious Diseases|February 23, 2019
Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral TherapyPriya Bhagwat, Shashi N Kapadia, Heather J Ribaudo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Case-control study of diabetes mellitus in HIV-infected patientsCecilia Yoon, Roy M Gulick, Donald R Hoover, et al.
HIV Clinical Trials|February 6, 2010
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)David B Clifford, Scott Evans, Yijun Yang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2008
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095Bruce R Schackman, Heather J Ribaudo, Amy Krambrink, et al.
AIDS (London, England)|February 4, 2012
Novel clinical trial designs for the development of new antiretroviral agentsNina Mani, Jeffrey Murray, Roy M Gulick, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 13, 2010
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2W David Hardy, Roy M Gulick, Howard Mayer, et al.
The Journal of Infectious Diseases|March 20, 2004
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359Courtney V Fletcher, Hongyu Jiang, Richard C Brundage, et al.
Antiviral Therapy|February 22, 2007
Design issues in initial HIV-treatment trials: focus on ACTG A5095Heather J Ribaudo, Daniel R Kuritzkes, Bruce R Schackman, et al.
The Journal of Infectious Diseases|November 4, 2005
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virusKristen M Marks, Lydia M Petrovic, Andrew H Talal, et al.
Pageof 16